1377239-83-2

Basic information

• Product Name: PBTZ169
• Synonyms: 2-(4-(Cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one
• CAS NO: 1377239-83-2
• Molecular Formula: C₂₀H₂₃F₃N₄O₃S
• Molecular Weight: 456.4818296
• Mol File: 1377239-83-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PBTZ169(CAS DataBase Reference)
• NIST Chemistry Reference: PBTZ169(1377239-83-2)
• EPA Substance Registry System: PBTZ169(1377239-83-2)

Safety Data

• Hazardous Substances Data: 1377239-83-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PBTZ169 is used as an antimycobacterial agent for the treatment of tuberculosis. Its potent bactericidal activity against M. tuberculosis in vitro and the ability to reduce bacterial burden in lung and spleen tissues in a mouse model of chronic tuberculosis make it a promising candidate for further development and potential clinical application.
Used in Research and Development:
PBTZ169 serves as a valuable tool in the study of mycobacterial cell wall synthesis and the role of DprE1 in the pathogenesis of tuberculosis. It can be utilized in research to better understand the mechanisms of action and resistance development, as well as to identify potential synergistic drug combinations for more effective treatment strategies.
Used in Drug Resistance Studies:
PBTZ169's unique mechanism of action as an irreversible inhibitor of DprE1 makes it a useful compound in investigating drug resistance in mycobacteria. It can be employed to study the development of resistance to this class of inhibitors and to develop strategies to overcome or prevent resistance in tuberculosis treatment.
Used in Drug Delivery Systems:
As with other potent antimicrobial agents, PBTZ169 can be incorporated into drug delivery systems to improve its bioavailability, targeting, and overall therapeutic efficacy. This may involve the development of novel formulations, such as nanoparticles or liposomal encapsulation, to enhance the drug's performance in treating tuberculosis.

Upstream product

• 22227-59-4 2-chloro-3-nitro-5-(trifluoromethyl)benzoic acid 
• 87033-30-5 2-chloro-3-nitro-5-(trifluoromethyl)benzoyl chloride 
• 57184-23-3 1-cyclohexylmethylpiperazine 
• 2550-36-9 Cyclohexylmethyl bromide 
• 7755-92-2 piperazine-1-carbaldehyde 
• 22227-47-0 2-chloro-3-nitro-5-(trifluoromethyl)benzamide 

Relevant articles and documents

Macozinone: Revised synthesis and crystal structure of a promising new drug for treating drug-sensitive and drug-resistant tuberculosis

Mycobacterium tuberculosis (Mtb), the principal etiological agent of tuberculosis (TB), infects over one-quarter of humanity and is now the leading cause of infectious disease mortality by a single pathogen. Macozinone {2-[4-(cyclohexylmethyl)piperazin-1-

Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis

8-Nitrobenzothiazinones (BTZs) are a promising class of antimycobacterial agents currently under investigation in clinical trials. Starting from thiourea derivatives, a new synthetic pathway to BTZs was established. It allows the formation of the thiazinone ring system in one synthetic step and is applicable for preparation of a wide variety of BTZ analogues. The synthetic procedure furthermore facilitates the replacement of the sulphur atom in the thiazinone ring system by oxygen or nitrogen to afford the analogous benzoxazinone and quinazolinone systems. 36 BTZ analogues were prepared and tested in luminescence-based assays for in vitro activity against Mycobacterium tuberculosis (Mtb) using the microdilution broth method and a high-throughput macrophage infection assay.

2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS

The present invention relates to new 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections caused by bacteria, especially diseases like tuberculosis (TB), Buruli ulcer and leprosy that result from i

2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS

The present invention relates to new 2-piperazin-1-yl-4H-1,3-benzothiazin- 4-one derivatives and their use for the treatment of mammalian infections caused by bacteria, especially diseases like tuberculosis (TB), Buruli ulcer and leprosy that result from